AMENDMENT TO THE SPECIFICATION:

Please replace the paragraph on page 1, after the title, with the following amended paragraph:

This application is a continuation of application Serial No. 09/564,504 filed May 4, 2000 ~~2002~~, now abandoned, which is a divisional of application Serial No. 08/532,384 filed September 22, 1995, now U.S. Patent No. 6,083,904 ~~6,083,590~~, which is a continuation application of Serial No. 08/083,590 filed June 25, 1993, now U.S. Patent No. 5,786,158, which is a continuation-in-part of both co-pending application Serial No. 07/955,012 filed September 30, 1992, and co-pending application Serial No. 07/879,038 filed April 30, 1992, both now abandoned, each of which is incorporated by reference herein in its entirety.

Please replace the paragraph bridging pages 17-18 beginning with "The Antagonist Therapeutics" with the following amended paragraph:

The Antagonist Therapeutics are administered therapeutically (including prophylactically): (1) in diseases or disorders involving increased (relative to normal, or desired) levels of Notch function, for example, where the Notch protein is overexpressed or overactive; and (2) in diseases or disorders wherein *in vitro* (or *in vivo*) assays indicate the utility of Notch antagonist administration. The disease or disorder can be a malignancy characterized by increased Notch activity or increased expression of a Notch protein or of a Notch derivative capable of being bound by an anti-Notch antibody, relative to said Notch activity or expression in an analogous non-malignant sample. The increased levels of Notch function can be readily detected by methods such as those described above, by quantifying protein and/or RNA. *In vitro* assays with cells of patient tissue sample or the appropriate cell line or cell type, to determine therapeutic utility, can be carried out as described above.